Samsung Medical Center Leading the Way in CAR-T Cell Therapy in Asia
Samsung Medical Center Leading the Way in CAR-T Cell Therapy in Asia.
On June 24-25, a team from National Taiwan University Hospial visited Samsung Medical Center’s CAR-T Therapy Center to gain insights and expertise in CAR-T cell therapy.
Samsung Medical Center was the first in South Korea to introduce CAR-T cell therapy in April 2021, initially treating patients with refractory B-cell lymphoma. By last year, the hospital had achieved a significant milestone of 100 CAR-T treatments, and as of June this year, that number has risen to 175, reflecting a rapid advancement in their capabilities.
Dr. Won Seog Kim, Director of the CAR-T Therapy Center, stated, “We aim to not only be the first in the country to offer CAR-T cell therapy but also become the best at it. Our goal is to provide a broader range of treatment options, ensuring that more patients with blood cancers receive the highest quality of care.”